Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7507871 | Drug and Alcohol Dependence | 2012 | 7 Pages |
Abstract
Psychedelic EPS use appears largely restricted to a distinct subset of REU with high-level non-injecting polydrug use, but use appears generally limited. The demographic similarity of stimulant EPS consumers with 'mainstream' REU, in conjunction with positive responses to the psychoactive effects of these drugs and declining ecstasy purity, suggests strong potential for stimulant EPS to expand further into ecstasy markets. Such drugs may have a greater public health impact than ecstasy, and merit careful monitoring into the future.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Raimondo Bruno, Allison J. Matthews, Matthew Dunn, Rosa Alati, Fairlie McIlwraith, Sophie Hickey, Lucy Burns, Natasha Sindicich,